Evidence map›Paper›PMID 22585916›Full record

ReviewAdvances in nutrition (Bethesda, Md.)2012

Structure-function relationships of human milk oligosaccharides.

Lars Bode, Evelyn Jantscher-Krenn

Open access · bronzeAbstract readReview
In one paragraph

Review in Advances in nutrition (Bethesda, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 2 pooled it
8.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 2 syntheses or guidelines pooled it, 317 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Secretor status-dependent modulation ofFrontiers in nutrition · 2026
    Article
  17. Article
  18. Metabolic interactions and growth dynamics ofFrontiers in microbiology · 2026
    Article
  19. Article
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lars BodeDivision of Neonatology and Division of Gastroenterology and Nutrition, Department of Pediatrics, University of California, San Diego, CA, USA. lbode@ucsd.edu
Evelyn Jantscher-Krenn
University of California San Diego · US

Funding

Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing EnterocolitisR00DK078668 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BODE, LARS · 2009 to 2011
$747k
Fusing Glycobiology and Nutritional Sciences to Prevent Necrotizing EnterocolitisK99DK078668 · NIDDK · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI BODE, LARS · 2008 to 2009
$181k
NIDDK NIH HHS K99 DK078668NIDDK NIH HHS K99/R00 DK078668NIDDK NIH HHS R00 DK078668
6 · The paper itself

Abstract

Human milk contains more than a hundred structurally distinct oligosaccharides. In this review, we provide examples of how the structural characteristics of these human milk oligosaccharides (HMO) determine functionality. Specific α1-2-fucosylated HMO have been shown to serve as antiadhesive antimicrobials to protect the breast-fed infant against infections with Campylobacter jejuni, one of the most common causes of bacterial diarrhea. In contrast, α1-2-fucosylation may abolish the beneficial effects of HMO against Entamoeba histolytica, a protozoan parasite that causes colitis, acute dysentery, or chronic diarrhea. In a different context, HMO need to be both fucosylated and sialylated to reduce selectin-mediated leukocyte rolling, adhesion, and activation, which may protect breast-fed infants from excessive immune responses. In addition, our most recent data show that a single HMO that carries not 1 but 2 sialic acids protects neonatal rats from necrotizing enterocolitis, one of the most common and often fatal intestinal disorders in preterm infants. Oligosaccharides currently added to infant formula are structurally different from the oligosaccharides naturally occurring in human milk. Thus, it appears unlikely that they can mimic some of the structure-specific effects of HMO. Recent advances in glycan synthesis and isolation have increased the availability of certain HMO tri- and tetrasaccharides for in vitro and in vivo preclinical studies. In the end, intervention studies are needed to confirm that the structure-specific effects observed at the laboratory bench translate into benefits for the human infant. Ultimately, breastfeeding remains the number one choice to nourish and nurture our infants.

Indexed as

AnimalsAnti-Infective AgentsBreast FeedingCampylobacter InfectionsCampylobacter jejuniDiarrheaEntamoeba histolyticaEnterocolitis, NecrotizingHumansInfantInfant FormulaInfant, NewbornInfant, PrematureIntestinal DiseasesMilk, HumanOligosaccharidesAnti-Infective AgentsOligosaccharidesSialic Acids

Identifiers

PMID22585916
PMCPMC3649474
OpenAlexW2157171377

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.